Skip to main content
. 2013 Dec 2;124(1):188–197. doi: 10.1172/JCI69856

Figure 3. 4-1BB-raptor conjugate promotes the persistence of OT-I cells in mice.

Figure 3

CD45.2 C57BL/6 mice were transferred with congenic CD45.1 OT-I cells, activated in situ with OVA peptide, and treated either with rapamycin or with 4-1BB-GFP or 4-1BB-raptor conjugates. Cells were isolated from the blood or spleen, stained with antibodies, and analyzed by flow cytometry. (A) Percentage of CD44hi/CD62Lhi OT-I cells in the spleen on day 5. Cells were stained with Pacific Blue CD8, PE-CD44, and FITC-CD45.1 APC-CD62L antibodies (n = 8). (B) Percentage of CD62hi/CD127hi OT-I cells in the spleen on day 8. Cells were stained with Pacific Blue CD8, APC-CD127, and FITC-CD45.1 PE-CD62L antibodies (n = 2). (C) CD8+CD45.1+ OT-I cells in the blood (5 mice per group). Statistical analysis for 4-1BB raptor versus 4-1BB-GFP, P = 0.0004; rapamycin versus untreated, P = 0.0003 (n = 2). (D) CD8+CD45.1+ OT-I cells in the spleen on day 28 (n = 7).